EW - Edwards Lifesciences Corporation
| Previous Close | 147.32 |
| Open | 147.91 |
| Bid | 136.76 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 145.18 - 149.07 |
| 52 Week Range | 100.20 - 175.00 |
| Volume | 4,373,502 |
| Avg. Volume | 1,560,398 |
| Market Cap | 30.449B |
| Beta (3Y Monthly) | 0.53 |
| PE Ratio (TTM) | 47.76 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks•2 days ago
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
Edwards Lifesciences (EW) closed the most recent trading day at $145.51, moving -1.23% from the previous trading session.
Market Realist•2 days agoGauging Analysts’ Views for NovoCure Stock
Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.” The mean rating for NovoCure is 1.6 with a target price of $56.50. That implies an upside potential of 24.4% over its trading price of $45.42 on October 18.
Market Realist•2 days agoNovoCure’s Operational Performance in Q3 2018: What to Expect
NovoCure’s (NVCR) gross income is expected to rise 28.22% to $44.82 million in the third quarter of 2018. Its gross margin is expected to contract from 69.76% in the third quarter of fiscal 2017 to 68.7% in the third quarter of fiscal 2018. NovoCure’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 67.97% and 72.72%, respectively.
Markit•3 days agoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Zacks•3 days ago
Will Edwards' (EW) Steady Overall Growth Drive Q3 Earnings?
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q3.
- Zacks•4 days ago
Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed
Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.
GuruFocus.com•4 days agoBarclays Takes Action on Health Care Stocks
The firm has initiated coverage of Abbott Labs, Boston Scientific, Medtronic, Stryker and others
- Market Realist•9 days ago
Edwards Lifesciences’ Q3 2018 Earnings Estimates
Edwards Lifesciences (EW) will release its third-quarter earnings results on October 23. The company is expected to register adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.
Market Realist•9 days agoWhat to Expect of Edwards Lifesciences’ Q3 2018 Sales
Edwards Lifesciences (EW) is scheduled to announce its third-quarter earnings results after the market closes on October 23. The company is a leading player in the artificial heart valve market.
Market Realist•9 days agoAnalysts Raise Their Targets on EW ahead of Its Q3 2018 Results
Edwards Lifesciences (EW) is a leading transcatheter heart valve manufacturer in the United States. The company is set to release its third-quarter earnings results after the market closes on October 23. In this article, we’ll look at analysts’ recommendations and target prices for EW ahead of its third-quarter earnings release. According to an October 12 Reuters survey, which included 21 analysts covering EW stock, 62% of analysts (or 13) have recommended “buys” or “strong buys” on Edwards Lifesciences.
- Zacks•9 days ago
Is Edwards Lifesciences (EW) Stock Outpacing Its Medical Peers This Year?
Is (EW) Outperforming Other Medical Stocks This Year?
Market Realist•9 days agoA Look at Abbott Laboratories’ Third-Quarter Earnings Estimates
On October 17, before the market opens, Abbott Laboratories plans to announce its earnings results for the third quarter of 2018. Wall Street expects Abbott to register Q3 adjusted EPS (earnings per share) of $0.74, which would be a YoY (year-over-year) increase of 12.9%. In the second quarter, it reported adjusted EPS of $0.73, up 17.7% YoY, which exceeded analysts’ estimates.
- Zacks•11 days ago
Can Edwards Lifesciences (EW) Keep the Earnings Surprise Streak Alive?
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks•12 days ago
Edwards Begins US CENTERA Study, Reintroduces Valve in Europe
Edwards (EW) is recommencing commercial introduction of CENTERA valve in Europe after making certain minor modification to CENTERA's delivery system.
- CNBC•13 days ago
After-hours buzz: TSLA, EW & more
Check out the companies making headlines after the bell: Tesla TSLA shares rose 1 percent in after-hours trading after investment firm Macquarie gave the automaker an 'outperform' rating and a price target of $430.
Markit•13 days agoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Market Realist•13 days ago
Boston Scientific Expects 6.4%–7.4% Sales Growth in Fiscal 2018
During the investor update at the TCT (Transcatheter Cardiovascular Therapeutics) meeting on September 24, Boston Scientific increased its long-term outlook. For 2019 and 2020, it now expects operational sales growth of 7%–10%, which compares to the previous guidance of 6%–9%. It expects growth to be driven by both organic and inorganic growth.
Market Realist•16 days agoHow Important Are Boston Scientific’s Valuation Multiples?
On October 4, Boston Scientific (BSX) was trading at a forward PE ratio of 24.7x compared to the industry average of 22.9x. Let’s look at another key valuation multiple, the EV-to-EBITDA ratio, which is a capital structure–neutral valuation metric. Boston Scientific’s forward EV-to-EBITDA multiple is 19.4x, which is higher than the industry average of 17.3x.
Market Realist•16 days agoAnalysts Still Bullish on Boston Scientific Stock in October
Boston Scientific (BSX) stock traded at its 52-week high on October 2. It has seen tremendous growth momentum over the past year on the back of strong product launches, approvals, and acquisitions.
Market Realist•16 days agoWhat Triggered a 52-Week High for Boston Scientific in October?
Boston Scientific Has Massive Bull Run: Is There More Upside? On October 3, Boston Scientific (BSX) stock closed at $38.61, a decline of ~1.1% compared to $39.04 on October 2. It hit a 52-week high of $39.44 during the day on October 2 when Morgan Stanely raised its target price.
- Zacks•17 days ago
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
- CNBC Videos•13 days ago
Cramer's lightning round: 'Don't run from' the declining ...
Jim Cramer flies through his take on callers' favorite stocks, including medical device play Edwards Lifesciences.
